New blood filter aims to save lives in liver failure and sepsis
NCT ID NCT06562803
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a special blood-filtering device (DPCAS+LPE) in 192 adults with acute-on-chronic liver failure and sepsis. The device removes harmful inflammatory substances from the blood. Researchers will compare survival rates and organ function between patients receiving this device plus standard care versus standard care alone. The goal is to see if this approach can reduce deaths within 4 and 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
double plasma cytokine adsorption system with sequential low-dose plasma exchange (DPCAS+LPE) device
What this could lead to
If successful, this could offer a new treatment option to improve survival in patients with severe liver failure complicated by sepsis.
What could go wrong
This is a mid-stage trial with 192 participants, so results may not apply to all patients. The device is complex and carries risks like bleeding or infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Third Affiliated Hospital of Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510630, China
Contact Phone: •••-•••-•••• Email: •••••@•••••